Catalyst Biosciences Shares Outstanding 2006-2021 | CBIO

Catalyst Biosciences shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Catalyst Biosciences Annual Shares Outstanding
(Millions of Shares)
2020 19
2019 12
2018 11
2017 3
2016 1
2015 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2007 0
2006 0
2005 0
Catalyst Biosciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 31
2021-03-31 28
2020-12-31 19
2020-09-30 22
2020-06-30 18
2020-03-31 15
2019-12-31 12
2019-09-30 12
2019-06-30 12
2019-03-31 12
2018-12-31 11
2018-09-30 12
2018-06-30 12
2018-03-31 9
2017-12-31 3
2017-09-30 4
2017-06-30 4
2017-03-31 1
2016-12-31 1
2016-09-30 1
2016-06-30 1
2016-03-31 1
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31 0
2013-09-30 0
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31 0
2008-09-30 0
2008-06-30 0
2008-03-31 0
2007-12-31 0
2007-09-30 0
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.110B $0.021B
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57